HSBC Upgrades Moderna to Hold, Announces $82 Price Target
Portfolio Pulse from Benzinga Newsdesk
HSBC analyst Yifeng Liu has upgraded Moderna (NASDAQ:MRNA) from Reduce to Hold, setting a price target of $82.

August 28, 2024 | 11:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HSBC has upgraded Moderna from Reduce to Hold, with a new price target of $82, indicating a more neutral stance on the stock.
The upgrade from Reduce to Hold by HSBC suggests a more positive outlook on Moderna's stock, which could lead to a short-term increase in investor confidence and potentially a positive impact on the stock price. The new price target of $82 provides a specific valuation benchmark for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100